Agenus Reports Three-Year Survival Data for BOT+BAL in MSS mCRC
Event summary
- Agenus will present three-year survival data from the Phase 1b C-800-01 study of botensilimab plus balstilimab in MSS mCRC without active liver metastases at ESMO GI 2026.
- The poster presentation, delivered by Benjamin L. Schlechter, MD, provides updated findings from a fully enrolled cohort of 123 patients.
- This follows the two-year overall survival data presented at ESMO-GI 2025, reflecting an additional year of follow-up.
The big picture
Agenus' presentation of three-year survival data for its BOT+BAL combination therapy in MSS mCRC comes at a critical juncture for immuno-oncology treatments targeting 'cold' tumors. The extended follow-up results could validate the company's approach to expanding immunotherapy benefits beyond traditional responders, potentially positioning Agenus as a key player in the evolving cancer treatment landscape.
What we're watching
- Clinical Efficacy
- How the three-year survival data will compare to previous two-year results and whether it supports further development of BOT+BAL in MSS mCRC.
- Regulatory Pathway
- The pace at which Agenus can advance BOT+BAL through subsequent clinical trials based on these extended follow-up results.
- Market Positioning
- Whether Agenus can leverage this data to differentiate its combination therapy in the competitive immuno-oncology landscape.
Related topics